Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Orgenesis Inc. (ORGS : NSDQ)
 
 • Company Description   
Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD.

Number of Employees: 151

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.07 Daily Weekly Monthly
20 Day Moving Average: 61,586 shares
Shares Outstanding: 24.82 (millions)
Market Capitalization: $51.38 (millions)
Beta: 0.90
52 Week High: $5.85
52 Week Low: $2.03
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -35.51% -29.39%
12 Week -35.71% -27.75%
Year To Date -28.13% -12.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
20271 Goldenrod Lane
-
Germantown,MD 20876
USA
ph: 480-659-6404
fax: -
orgs@crescendo-ir.com http://www.orgenesis.com
 
 • General Corporate Information   
Officers
Vered Caplan - Chief Executive Officer and Chairperson of theBoar
Neil Reithinger - Chief Financial Officer; Treasurer and Secretary
Guy Yachin - Director
David Sidransky - Director
Yaron Adler - Director

Peer Information
Orgenesis Inc. (CORR.)
Orgenesis Inc. (RSPI)
Orgenesis Inc. (CGXP)
Orgenesis Inc. (BGEN)
Orgenesis Inc. (GTBP)
Orgenesis Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 68619K204
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/27/22
Share - Related Items
Shares Outstanding: 24.82
Most Recent Split Date: 11.00 (0.08:1)
Beta: 0.90
Market Capitalization: $51.38 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 6.47
PEG Ratio: -
Price Ratios
Price/Book: 1.30
Price/Cash Flow: -
Price / Sales: 1.49
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -147.62%
Sales Growth
vs. Year Ago Period: 200.17%
vs. Previous Quarter: -9.39%
ROE
03/31/22 - -
12/31/21 - 16.12
09/30/21 - -76.79
ROA
03/31/22 - -
12/31/21 - 10.73
09/30/21 - -51.67
Current Ratio
03/31/22 - -
12/31/21 - 1.68
09/30/21 - 2.68
Quick Ratio
03/31/22 - -
12/31/21 - 1.67
09/30/21 - 2.67
Operating Margin
03/31/22 - -
12/31/21 - 22.02
09/30/21 - -130.13
Net Margin
03/31/22 - -
12/31/21 - 22.02
09/30/21 - -112.03
Pre-Tax Margin
03/31/22 - -
12/31/21 - -50.56
09/30/21 - -221.07
Book Value
03/31/22 - -
12/31/21 - 1.59
09/30/21 - 1.78
Inventory Turnover
03/31/22 - -
12/31/21 - 234.90
09/30/21 - 422.92
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.13
09/30/21 - 0.17
Debt-to-Capital
03/31/22 - -
12/31/21 - 11.25
09/30/21 - 14.48
 

Powered by Zacks Investment Research ©